Journal article

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

Ira Jacobson, Stefan Zeuzem, Robert Flisiak, Brygida Knysz, Stefan Lueth, Dorota Zarebska-Michaluk, Ewa Janczewska, Peter Ferenci, Moises Diago, Anna Linda Zignego, Rifaat Safadi, Yaacov Baruch, Dzhamal Abdurakhmanov, Stephen Shafran, Dominique Thabut, Rafael Bruck, Adrian Gadano, Alexander James Thompson, Justin Kopit, Fiona McPhee Show all

World Journal of Gastroenterology | BAISHIDENG PUBLISHING GROUP INC | Published : 2016

DOI: 10.3748/wjg.v22.i12.3418

Grants

Funding Acknowledgements

Supported by Bristol-Myers Squibb.

Citation metrics

11Web of Science
11Scopus

Keywords

Drug Therapy, Combination
Interferon-Alpha 2a
Interferon-Alpha
Direct-Acting Antiviral
Gastroenterology & Hepatology
Chronic Hepatitis C
Viral Nonstructural Proteins
Recombinant Proteins
Genotype
Humans
Imidazoles
Polyethylene Glycols
Pegylated Interferon
Abt-450/r-Ombitasvir
Double-Blind
Hepatitis C, Chronic
Phase-3
Treatment Outcome
Time Factors
Simeprevir
Life Sciences & Biomedicine
Male
Aged
Daclatasvir
Young Adult
Adolescent
Genotype 1b
Female
Ns5a Inhibitor
Rna, Viral
Oligopeptides
Interferons
Hcv
Hepacivirus
Polymorphism, Genetic
Antiviral Agents
Ribavirin
Liver Disease
Treatment-Naive Patients
Middle Aged
Interleukins
Drug Resistance, Viral
Viral Load
Science & Technology
Adult
Infection